Company
Denali Therapeutics
Denali Therapeutics has 13 drugs tracked on RxWires: 2 in Phase 2/3, 1 in Phase 2, 2 in Phase 1/2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| DNL343 | Phase 2/3 | Amyotrophic Lateral Sclerosis |
| tividenofusp alfa | Phase 2/3 | Mucopolysaccharidosis II |
| BIIB122 225 mg | Phase 2 | Parkinson Disease |
| DNL126 | Phase 1/2 | Mucopolysaccharidosis Type IIIA |
| DNL593 | Phase 1/2 | Frontotemporal Dementia |
| DNL201 | Phase 1 | Healthy Volunteers |
| DNL919 | Phase 1 | Healthy Participant |
| DNL628 | Phase 1 | Alzheimer Disease, Early Onset |
| DNL952 | Phase 1 | Late-onset Pompe Disease |
| DNL921 | Phase 1 | Alzheimer's Disease |
| [14C]-DNL343 | Phase 1 | Healthy Volunteers |
| DNL747 | Phase 1 | Alzheimer Disease |
| DNL151 | Phase 1 |
Latest
- denali therapeutics filed 8-K
- denali therapeutics filed 8-K
- Priority Review: denali therapeutics
- Priority Review: denali therapeutics
- denali therapeutics filed 8-K
Follow Denali Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.